JP2010540543A5 - - Google Patents

Download PDF

Info

Publication number
JP2010540543A5
JP2010540543A5 JP2010527035A JP2010527035A JP2010540543A5 JP 2010540543 A5 JP2010540543 A5 JP 2010540543A5 JP 2010527035 A JP2010527035 A JP 2010527035A JP 2010527035 A JP2010527035 A JP 2010527035A JP 2010540543 A5 JP2010540543 A5 JP 2010540543A5
Authority
JP
Japan
Prior art keywords
substituted
heteroaryl
disease
aryl
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2010527035A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010540543A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2008/076792 external-priority patent/WO2009042485A1/en
Publication of JP2010540543A publication Critical patent/JP2010540543A/ja
Publication of JP2010540543A5 publication Critical patent/JP2010540543A5/ja
Pending legal-status Critical Current

Links

JP2010527035A 2007-09-24 2008-09-18 スフィンゴシン‐1‐リン酸(s1p)レセプター生物学的活性を有するアリールまたはヘテロアリール基を担持するインドール化合物 Pending JP2010540543A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US97451107P 2007-09-24 2007-09-24
PCT/US2008/076792 WO2009042485A1 (en) 2007-09-24 2008-09-18 Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (s1p) receptor biological activity

Publications (2)

Publication Number Publication Date
JP2010540543A JP2010540543A (ja) 2010-12-24
JP2010540543A5 true JP2010540543A5 (enExample) 2011-11-10

Family

ID=40042883

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2010527035A Pending JP2010540543A (ja) 2007-09-24 2008-09-18 スフィンゴシン‐1‐リン酸(s1p)レセプター生物学的活性を有するアリールまたはヘテロアリール基を担持するインドール化合物

Country Status (10)

Country Link
US (1) US7888336B2 (enExample)
EP (1) EP2203424A1 (enExample)
JP (1) JP2010540543A (enExample)
KR (1) KR20100067677A (enExample)
CN (1) CN101918360A (enExample)
AU (1) AU2008304657B2 (enExample)
BR (1) BRPI0817397A2 (enExample)
CA (1) CA2700539A1 (enExample)
RU (1) RU2010112275A (enExample)
WO (1) WO2009042485A1 (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006088246A1 (ja) * 2005-02-18 2006-08-24 Takeda Pharmaceutical Company Limited Gpr34受容体機能調節剤
US8524917B2 (en) * 2007-01-11 2013-09-03 Allergan, Inc. 6-substituted indole-3-carboxylic acid amide compounds having sphingosine-1-phosphate (S1P) receptor antagonist biological activity
US8513418B2 (en) * 2011-04-18 2013-08-20 Allergan, Inc. Substituted bicyclic methyl amine derivatives as sphingosine-1 phosphate receptors modulators
GB201603745D0 (en) * 2016-03-04 2016-04-20 Galapagos Nv Novel compounds and pharmaceutical compositions thereof for the treatment of fibrosis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4363912A (en) * 1980-12-15 1982-12-14 Pfizer Inc. Indole thromboxane synthetase inhibitors
EP0146810A3 (de) * 1983-12-05 1987-05-13 Solco Basel AG Verfahren zur Herstellung von Sphingosinderivaten
US5110987A (en) * 1988-06-17 1992-05-05 Emory University Method of preparing sphingosine derivatives
ZA902794B (en) * 1989-04-18 1991-04-24 Duphar Int Res New 3-n substituted carbamoyl-indole derivatives
US5294722A (en) * 1992-04-16 1994-03-15 E. R. Squibb & Sons, Inc. Process for the preparation of imidazoles useful in angiotensin II antagonism
US5403851A (en) * 1994-04-05 1995-04-04 Interneuron Pharmaceuticals, Inc. Substituted tryptamines, phenalkylamines and related compounds
US5639780A (en) * 1995-05-22 1997-06-17 Merck Frosst Canada, Inc. N-benzyl indol-3-yl butanoic acid derivatives as cyclooxygenase inhibitors
US5811425A (en) * 1997-03-04 1998-09-22 Abbott Laboratories Heterocyclic compounds as COX-2 inhibitors
JP4001929B2 (ja) * 1997-03-12 2007-10-31 タカラバイオ株式会社 スフィンゴシン類縁化合物
AU9002298A (en) * 1997-09-11 1999-03-29 Takara Shuzo Co., Ltd. Sphingosine derivatives and medicinal composition
US6358992B1 (en) * 1998-11-25 2002-03-19 Cell Pathways, Inc. Method of inhibiting neoplastic cells with indole derivatives
FR2814073B1 (fr) * 2000-09-21 2005-06-24 Yang Ji Chemical Company Ltd Composition pharmaceutique antifongique et/ou antiparasitaire et nouveaux derives de l'indole a titre de principes actifs d'une telle composition
WO2003000253A1 (en) * 2001-06-20 2003-01-03 Wyeth Substituted indole acid derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1)
AU2003214873A1 (en) 2002-01-18 2003-09-02 Ceretek Llc Methods of treating conditions associated with an edg receptor
ATE441654T1 (de) 2002-01-18 2009-09-15 Merck & Co Inc Edg-rezeptoragonisten
US7323479B2 (en) 2002-05-17 2008-01-29 Celgene Corporation Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline
CA2515638A1 (en) 2003-02-11 2004-08-26 Shifeng Pan Novel bicyclic compounds and compositions
WO2004096752A1 (en) 2003-04-30 2004-11-11 Novartis Ag Amino-propanol derivatives as sphingosine-1-phosphate receptor modulator
MY150088A (en) 2003-05-19 2013-11-29 Irm Llc Immunosuppressant compounds and compositions
US7582773B2 (en) * 2003-09-25 2009-09-01 Wyeth Substituted phenyl indoles
JP2009526863A (ja) 2006-02-15 2009-07-23 アラーガン、インコーポレイテッド スフィンゴシン−1−リン酸(s1p)受容体アンタゴニスト生物学的活性を有するアリールまたはヘテロアリール基を持つインドール−3−カルボン酸アミド、エステル、チオアミドおよびチオールエステル化合物
WO2007112322A2 (en) * 2006-03-28 2007-10-04 Allergan, Inc. Indole compounds having sphingosine-1-phosphate (s1p) receptor agonist and/or antagonist biological activity

Similar Documents

Publication Publication Date Title
AU2007265455B2 (en) Human protein tyrosine phosphatase inhibitors and methods of use
US7112594B2 (en) Fused bicyclic amide compounds and medicinal use thereof
RU2005137403A (ru) Новые замещенные 3-сера-индолы
RU2576036C2 (ru) Модуляторы активности нес1 и способы для них
JP2005522438A5 (enExample)
RU2019123031A (ru) (аза)индол-, бензотиофен- и бензофуран-3-сульфонамиды
JP2005509024A5 (enExample)
JP2016505551A5 (enExample)
JP2009523165A5 (enExample)
JP2010540543A5 (enExample)
RU2004127925A (ru) N3-алкилированные бензимидазольные производные в качестве ингибиторов мек
RU2004117887A (ru) Ариланилиновые агонисты бета2 адренергических рецепторов
JP2009530304A5 (enExample)
BRPI0508570B1 (pt) composto, composição farmacêutica, e, uso da mesma
RU2011153772A (ru) Фторированные аминотриазольные производные
JP2009501775A (ja) 癌治療におけるチアゾール誘導体およびアナログの使用
CA3086662A1 (en) Nitrogen-containing 6-membered cyclic compound
RU2005137155A (ru) Производные 9-азабицикло [3.3.1] нон-6-ена с гетероатомом на позиции 3 как ингибиторы ренина
JP2006516626A5 (enExample)
RU2010112275A (ru) Индольные соединения, содержащие арильные или гетероарильные группы, обладющие биологической активностью рецептора сфингозин-1-фосфата (с1ф)
JP2013526560A5 (enExample)
JP2004035485A (ja) テロメラーゼ阻害剤
US8143291B2 (en) Indole compounds bearing aryl or heteroaryl groups having sphingosine-1-phosphate (S1P) receptor biological activity
HK1129388B (en) Human protein-tyrosine phosphatase inhibitors and their pharmaceutical use
MX2008000972A (en) Use of thiazole derivatives and analogues in the treatment of cancer